Clinical Trial

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Study acronym: CLOVER-2
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2018-03-26; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2023-05-16
Status change: Not Yet Recruiting → Recruiting 2019-03-18
Trial Details
NCT Number NCT03478462
Lead Sponsor Cellectar Biosciences, Inc.
Conditions Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
Enrollment 30 participants
Start Date 2019-04-30
Primary Completion 2026-08-25 (estimated)
Study Completion 2027-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-18